Idorsia Ltd. (IDRSF)
5.38
-0.02
(-0.37%)
USD |
OTCM |
Oct 02, 16:00
Idorsia Enterprise Value : 2.970B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.970B |
| October 01, 2026 | 2.975B |
| September 30, 2026 | 2.920B |
| September 29, 2026 | 2.920B |
| September 28, 2026 | 2.920B |
| September 25, 2026 | 2.949B |
| September 24, 2026 | 2.949B |
| September 23, 2026 | 3.028B |
| September 22, 2026 | 3.167B |
| September 21, 2026 | 3.167B |
| September 18, 2026 | 3.167B |
| September 17, 2026 | 3.167B |
| September 16, 2026 | 3.173B |
| September 15, 2026 | 3.173B |
| September 14, 2026 | 3.173B |
| September 11, 2026 | 3.173B |
| September 10, 2026 | 3.173B |
| September 09, 2026 | 3.204B |
| September 08, 2026 | 3.204B |
| September 04, 2026 | 3.196B |
| September 03, 2026 | 3.196B |
| September 02, 2026 | 3.199B |
| September 01, 2026 | 3.265B |
| August 31, 2026 | 3.265B |
| August 28, 2026 | 3.462B |
| Date | Value |
|---|---|
| August 27, 2026 | 3.462B |
| August 26, 2026 | 3.462B |
| August 25, 2026 | 3.462B |
| August 24, 2026 | 3.462B |
| August 21, 2026 | 3.462B |
| August 20, 2026 | 3.478B |
| August 19, 2026 | 3.478B |
| August 18, 2026 | 3.478B |
| August 17, 2026 | 3.593B |
| August 14, 2026 | 3.593B |
| August 13, 2026 | 3.593B |
| August 12, 2026 | 3.633B |
| August 11, 2026 | 3.633B |
| August 10, 2026 | 3.383B |
| August 07, 2026 | 3.383B |
| August 06, 2026 | 3.383B |
| August 05, 2026 | 3.383B |
| August 04, 2026 | 3.383B |
| August 03, 2026 | 3.659B |
| July 31, 2026 | 3.659B |
| July 30, 2026 | 3.659B |
| July 29, 2026 | 3.659B |
| July 28, 2026 | 3.659B |
| July 27, 2026 | 3.709B |
| July 24, 2026 | 3.554B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 34.09B |
| AC Immune SA | 159.91M |
| CRISPR Therapeutics AG | 3.777B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -135.44M |
| Revenue (Quarterly) | 66.88M |
| Total Expenses (Quarterly) | 202.32M |
| EPS Diluted (Quarterly) | -0.5293 |
| Gross Profit Margin (Quarterly) | 72.13% |
| Profit Margin (Quarterly) | -202.5% |
| Earnings Yield | -30.69% |
| Normalized Earnings Yield | -24.51 |